Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  carmustine
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Not yet active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: AMC-097, NCI-2015-01745, 097, 9933, NCT02797470
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895
Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and under
Trial IDs: 2260.00, NCI-2010-00403, FHCRC-2260.00, 6733, FHCRC-IR-6733, NCT00716066
Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 75
Trial IDs: CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562
Ofatumumab, Etoposide, and Cytarabine Followed By Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 112525, NCI-2012-00863, NCT01555541
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
NovoTTF-100A in Combination with Bevacizumab and Carmustine in Treating Patients with Glioblastoma Multiforme in First Relapse
Status: Active
Phase: Phase II
Type: Treatment
Age: 22 and over
Trial IDs: UCDCC#249, NCI-2014-02628, 663113-2, NCT02348255
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Primary Refractory or Relapsed Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 08179, NCI-2011-03334, 112221, 116766, 119517, 121504, NCT01476839
Yttrium Y 90 Basiliximab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Mature T-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 14349, NCI-2015-00019, 116688, NCT02342782
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma with HIV Infection
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 66
Trial IDs: 2673.00, NCI-2014-02395, 2673, NCT02343666
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients with Relapsed High-Risk Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 11097, NCI-2015-01065, HEM-14099-LM, NCT02504359
Anti-CD20 Radioimmunotherapy before Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk B-Cell Malignancies
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9189, NCI-2015-00299, NCT02483000
Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 21 and under
Trial IDs: ASCIST, NCI-2014-00275, NCT02130869
Start Over